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Abstract
Background: Treatment guidelines recommend LDL-C as the primary target of therapy in patients with
hypercholesterolemia. Moreover, combination therapies with lipid-lowering drugs that have different mechanisms
of action are recommended when it is not possible to attain LDL-C targets with statin monotherapy.
Understanding which treatment or patient-related factors are associated with attaining a target may be clinically
relevant.
Methods: Data were pooled from two multicenter, randomized, double-blind studies. After stabilization on
simvastatin 20 mg, patients with coronary heart disease (CHD) alone and/or type 2 diabetes mellitus (T2DM) were
randomized to ezetimibe 10 mg/simvastatin 20 mg (EZ/Simva) or simvastatin 40 mg. The change from baseline in
low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), TC/
HDL-C ratio, triglycerides, and the proportion of patients achieving LDL-C < 2.6 mmol/L (100 mg/dL) after 6 weeks
of treatment were assessed, and factors significantly correlated with the probability of achieving LDL-C < 2.6
mmol/L in a population of high cardiovascular risk Italian patients were identified. A stepwise logistic regression
model was conducted with LDL-C < 2.6 mmol/L at endpoint as the dependent variable and study, treatment,
gender, age (≥65 years or < 65 years), as independent variables and baseline LDL-C (both as continuous and
discrete variable).
Results: EZ/Simva treatment (N = 93) resulted in significantly greater reductions in LDL-C, TC, and TC/HDL-C ratio
and higher attainment of LDL-C < 2.6 mmol/L vs doubling the simvastatin dose to 40 mg (N = 106). Study
[including diabetic patients (OR = 2.9, p = 0.003)], EZ/Simva treatment (OR = 6.1, p < 0.001), and lower baseline
LDL-C (OR = 0.9, p = 0.001) were significant positive predictors of LDL-C target achievement. When baseline LDL-C
was expressed as a discrete variable, the odds of achieving LDL-C < 2.6 mmol/L was 4.8 in favor of EZ/Simva
compared with Simva 40 mg (p < 0.001), regardless of baseline LDL-C level.
Conclusion: EZ/Simva is an effective therapeutic option for patients who have not achieved recommended LDL-C
treatment targets with simvastatin 20 mg monotherapy.
Trial Registration: Clinical trial registration numbers: NCT00423488 and NCT00423579
Introduction
Treatment guidelines recommend reducing low-density
lipoprotein cholesterol (LDL-C) as the primary target of
therapy for patients with hypercholesterolemia [1-4].
Although therapeutic lifestyle changes (smoking cessa-
tion, increased activity, and reduced fat intake) are the
cornerstone of population-based interventions, often
they are not sufficient to achieve recommended treat-
ment targets. HMG-CoA reductase inhibitors (statins)
are the first line of lipid-modifying treatment, the bene-
fits of which have been shown across coronary heart
disease (CHD) risk strata. These benefits have also been
documented in both genders, across a range of age
groups, and in patients with or without diabetes or
hypertension [5]. European, Canadian and US treatment
guidelines recommend combination therapy with lipid-
lowering drugs that have different mechanisms of action
when it is not possible to attain the lowest LDL-C
targets with statin monotherapy [1,3,4].
Ezetimibe is a cholesterol absorption inhibitor that
blocks biliary and dietary cholesterol absorption at the
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brush border of the intestine without affecting absorp-
tion of fat-soluble vitamins and triglycerides [6]. In
patients with primary hypercholesterolemia, studies of
ezetimibe monotherapy have demonstrated significantly
greater reductions in LDL-C levels compared with pla-
cebo [7,8], and when coadministered with a statin, ezeti-
mibe has been shown to be significantly more effective
at reducing LDL-C levels compared with statin mono-
therapy (reviewed in [9]). These results appear to be
consistent across risk strata [10-12] and age groups [13]
and in patients with metabolic syndrome [14] or type 2
diabetes mellitus (T2DM) [15,16].
When confronted with the choice of an alternative
treatment in high-risk patients not at target with statin
monotherapy, it would be clinically relevant to know
which treatment or patient-related factors might corre-
late with higher odds of attaining a target. The aim of
this pooled analysis of data from two multicenter, rando-
mized, double-blind studies in high-risk patients not at
target with simvastatin 20 mg/day [17,18] was to evaluate
the factors significantly correlated with the probability of
achieving the National Cholesterol Education Program
Adult Treatment Panel III (NCEP ATP III) recom-
mended LDL-C target < 2.6 mmol/L (100 mg/dL) after
6 weeks of treatment with EZ/Simva 10/20 mg vs
doubling the dose of simvastatin to 40 mg. The combined
analysis of data from these two studies with the same
design and treatment regimens provides a larger popula-
tion of patients at high cardiovascular risk in which to
evaluate the efficacy of the two treatment regimens.
Methods
Study design
The design was similar for both studies. Briefly, both
were multicenter, randomized, parallel-groups, double-
blind, double-dummy, placebo-controlled studies. Both
protocols were reviewed and approved by an Indepen-
dent Ethics Committee at each participating center; and
patients provided written, informed consent prior to any
study-related procedure being started. The studies were
conducted under the provisions of the Declaration of
Helsinki and in accordance with the International Con-
ference on Harmonization Consolidated Guidelines on
Good Clinical Practice.
Study population
In the LEAD study only [17], patients were required to
have adequately controlled T2DM (defined as fasting
plasma glucose > 126 mg/dL and hemoglobin (Hb) A1c
≤ 9.0%) of at least 12 months duration. In both studies
(LEAD and DIALOGUE), men and women ≥18 years
and ≤ 75 years of age with documented CHD, including
stable angina with evidence of ischemia on exercise test-
ing; history of myocardial infarction, percutaneous
transluminal coronary intervention, atherothrombotic
cerebrovascular disease, unstable angina or non-Q wave
myocardial infarction; or symptomatic peripheral vascu-
lar disease, who were taking a stable daily dose of sim-
vastatin 20 mg for 6 weeks with good compliance (80%
of daily doses for the 6 weeks prior to baseline visit),
and had LDL-C concentration ≥ 2.6 mmol/L (100 mg/
dL) to ≤ 4.1 mmol/L (160 mg/dL) were eligible for ran-
domization. Patients were instructed to follow a healthy
lifestyle (cholesterol-lowering diet and exercise)
throughout the study. In addition, subjects were
required to have triglyceride concentrations < 3.99
mmol/L (350 mg/dL), liver transaminases [alanine ami-
notransferase (ALT) or aspartate aminotransferase
(AST)] and creatine phosphokinase (CK) < 50% above
the upper limit of normal (ULN) with no active liver
disease, and hematology, blood chemistry, and urinalysis
within normal limits. Women of childbearing potential
were required to use birth control considered effective
by the investigators [17,18].
Patients were excluded if they had Class III or IV con-
gestive heart failure, uncontrolled cardiac arrhythmia;
recent (within 3 months of randomization) myocardial
infarction, acute coronary insufficiency, coronary artery
bypass surgery, or angioplasty; unstable or severe per-
ipheral artery disease; newly diagnosed or unstable
angina pectoris, uncontrolled hypertension (treated or
untreated); uncontrolled endocrine or metabolic disease
known to influence serum lipids or lipoproteins;
impaired renal function (creatinine > 2.0 mg/dL) or
nephrotic syndrome; or were taking any lipid-lowering
agents, fibrates, resins or niacin, or prescription and/or
over-the-counter-drugs with the potential for significant
lipid effects (other than study drug) or with potential
drug interactions with the statins.
Efficacy measures
Efficacy endpoints were those that were prespecified in the
trials prior to pooling the data. The percent change in
LDL-C from baseline to endpoint after 6 weeks of treat-
ment, the percentage of patients who reached LDL-C
< 2.6 mmol/L (100 mg/dL) at endpoint, and the percent
change from baseline to endpoint in total cholesterol,
high-density lipoprotein cholesterol (HDL-C), total choles-
terol/HDL-C and triglycerides were assessed after 6 weeks
of treatment. LDL-C measurements were calculated by the
Friedewald equation (all patients included in the study had
triglycerides < 4.52 mmol/L [ < 400 mg/dL]). Study, treat-
ment, gender, age, and baseline LDL-C were assessed as
potential predictors of LDL-C target achievement.
Tolerability
Adverse events were summarized by system organ class
and specific adverse experience term. Laboratory tests
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included complete blood count, total protein, albumin,
calcium, inorganic phosphorus, fasting plasma glucose
(FPG), blood urea nitrogen (BUN), uric acid, total biliru-
bin, alkaline phosphatase, ALT, AST, gamma glutamyl
transpeptidase (GGT), serum creatinine, thyroid stimu-
lating hormone (TSH; baseline only), HbA1c, sodium,
potassium, chloride, CK; and urinalysis.
Statistics
Efficacy endpoints were assessed in the intent-to-treat
(ITT) population, which included all subjects who
were randomized, had taken at least one dose of study
drug, and had at least one measurement at baseline
and after the start of treatment, using the ANOVA
model, which included terms for treatment effect. Fac-
tors significantly correlated with the probability of
achieving LDL-C < 2.6 mmol/L were assessed using a
stepwise logistic regression analysis with LDL-C < 2.6
mmol/L at endpoint as the dependent variable (yes/
no). Independent variables were study (T2DM, yes or
no), treatment, gender, age (≥65 years or < 65 years),
and baseline LDL-C, which was both a continuous and
discrete variable. The safety population included all
randomized patients who took at least one dose of
study drug. The incidence of adverse events was com-
pared between treatments using the Fisher exact test
with Yates correction if applicable.
Results
Population
The ITT population included 93 patients treated with
EZ/Simva 10/20 mg (n = 37 from LEAD and n = 56
from DIALOGUE) and 106 patients treated with Simva
40 mg (n = 50 from LEAD and n = 56 from DIALO-
GUE). Baseline characteristics for the combined popula-
tion are shown in Table 1. The mean age (± standard
deviation) was 63 ± 8 years in the EZ/Simva 10/20 mg
group and 63 ± 7 years in the Simva 40 mg group. All
patients were Caucasian and most patients were male
(55% in the EZ/Simva 10/20 mg group and 66% in the
Simva 40 group). Both treatment groups were generally
well-matched for demographic data, cardiovascular risk
factors, and baseline laboratory values. The mean LDL-
C was 3.3 mmol/L (126.2 mg/dL) in the EZ/Simva 10/
20 mg group and 3.3 mmol/L (127.1 mg/dL) in the
Simva 40 mg group. Ischemic heart disease was the
most common form of CHD reported, with 40 (43%)
patients in the EZ/Simva 10/20 mg group and 49 (46%)
patients in the Simva 40 mg group (Table 1). Major dif-
ferences between the studies included the level of fasting
plasma glucose, which was higher in the diabetic
patients compared with the non-diabetic patients, and
more women in the non-diabetic population vs the dia-
betic population [17,18].
Efficacy
Compared with doubling the dose of simvastatin to 40
mg, treatment with EZ/Simva 10/20 mg resulted in sig-
nificantly greater reductions from baseline in LDL-C,
total cholesterol, and total cholesterol/HDL-C ratio
(Figure 1; all p < 0.01); and significantly more patients
treated with EZ/Simva 10/20 mg achieved LDL-C < 2.6
mmol/L after 6 weeks of treatment (Figure 2; p < 0.01).
Changes in HDL-C and triglycerides were similar
between treatment groups (Figure 1).
Among the independent variables, participation in the
LEAD study (which included patients with T2DM; odds
Table 1 Baseline patient characteristics
Demographics EZ/Simva 10/20
(N = 93)
Simva 40
(N = 106)
Age, yrs mean (SD) 62.8 (7.9) 62.9 (7.1)
Females 42 (45%) 36 (34%)
Body mass index, kg/m2, mean (SD) 73.7 (11.6) 75.1 (12.7)
Current smokers 16 (17.2%) 21 (19.8%)
Hypertension 58 (62.4%) 56 (52.8%)
Diabetes 37 (39.8%) 50 (47.2%)
Laboratory values
mean (SD)
LDL-C (mmol/L) 3.27 (0.47) 3.29 (0.44)
TC (mmol/L) 5.18 (0.58) 5.18 (0.56)
HDL-C (mmol/L) 1.26 (0.30) 1.19 (0.26)
TC/HDL-C 4.31 (1.03) 4.54 (1.00)
Triglycerides (mmol/L) 1.45 (0.62) 1.52 (0.59)
AST (U/L) 19.8 (5.3) 20.6 (4.7)
ALT (U/L) 22.7 (9.5) 25.5 (9.7)
CK (U/L) 97.0 (44.1) 110.7 (46.2)
Prevalence of cardiovascular diseases, n (%)
Cerebrovascular disease 30 (32.3%) 30 (28.3%)
Peripheral vascular disease 32 (34.4%) 39 (36.8%)
Ischemic heart disease 40 (43.0%) 49 (46.2%)
ALT = alanine aminotransferase; AST = aspartate aminotransferase; CK =
creatine kinase;
EZ = ezetimibe; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-
density lipoprotein cholesterol; Simva = simvastatin; TC = total cholesterol
Figure 1 Change from treated baseline in LDL-C and other
lipids after 6 weeks of treatment. *p < 0.01
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ratio [OR] = 2.9, 95% confidence interval [CI]: 1.4-5.9; p
= 0.003) and EZ/Simva 10/20 treatment (OR = 6.1, 95%
CI: 2.9-12.4; p < 0.001) were significant, positive inde-
pendent predictors, and higher baseline LDL-C was a
significant, negative independent predictor (OR = 0.9,
95% CI: 0.93-0.97; p = 0.001) of achieving LDL-C < 2.6
mmol/L. When study was removed from the model, EZ/
Simva treatment remained a significant positive predic-
tor (OR = 5.0, 95% CI: 2.6-9.9; p < 0.01; Figure 3), and
higher baseline LDL-C remained a significant negative
predictor (OR = 0.9; 95% CI: 0.93-0.97; p < 0.01) of
LDL-C target achievement.
Tolerability results are summarized in Table 2. There
was no significant difference in the proportion of patients
who reported adverse events between treatment groups
(p = 0.606). No significant differences between groups
were observed in the number and rate of drug-related
adverse events, which were reported in 9.8% of patients
in the EZ/Simva 10/20 mg group and in 6.3% of patients
in the Simva 40 mg group (p = 0.500). There were few
discontinuations due to treatment-related adverse events
(only 1 patient in the EZ/Simva 10/20 mg group and 2 in
the Simva 40 mg group). Two serious adverse events
were reported: one in the EZ/Simva 10/20 mg group
(bone fracture) and one in the Simva 40 mg group (tran-
sient ischemic attack). Neither was considered drug-
related. There were no reports of increased ALT or AST
≥ 3 × ULN or CK ≥ 5-10 × ULN, and no deaths occurred
at any time during either study in either treatment group.
Discussion
The results of this pooled analysis were consistent with
those of the individual studies, confirming that,
compared with doubling the dose of simvastatin to 40
mg, treatment with EZ/Simva 10/20 mg produced signif-
icantly greater reductions in LDL-C, non-HDL-C, and
total cholesterol/HDL-C ratio; and significantly higher
proportions of patients achieved the NCEP ATP III-
recommended treatment target of LDL-C < 2.6 mmol/L
[17,18]. In addition, participation in the LEAD study
(which included CHD patients with T2DM), lower base-
line LDL-C, and treatment with EZ/Simva 10/20 mg
(regardless of baseline LDL-C) were positive predictors
of achieving LDL-C < 2.6 mmol/L in this high cardio-
vascular (CV) risk population with established CHD.
The results of this pooled analysis are in agreement
with those of previous studies that assessed the efficacy
of ezetimibe coadministered with a statin in high CV
risk populations pre-treated with statins but not at LDL-
C goal[10,12,19-21]. Taken together, these studies
demonstrate that patients with hypercholesterolemia
and CHD, who are at high CV risk and have not
attained recommended LDL-C treatment goals while on
statin, may benefit from ezetimibe added to statin ther-
apy through significantly greater improvements in LDL-
C and higher attainment of LDL-C treatment targets.
Knowledge of the factors that predict successful treat-
ment may have implications in the management of high
CV risk patients with hypercholesterolemia. It has been
shown that higher baseline LDL-C was a significant
negative predictor of LDL-C goal attainment, and this is
consistent with the results reported here [22,23]. Other
analyses have reported that two important independent
predictors of LDL-C goal attainment were appropriate
drug therapy and statin compliance [24,25]. Not surpris-
ingly, exercise, dietary compliance, and weight loss were
Figure 2 Proportion of patients achieving LDL-C < 2.6 mmol/L (100 mg/dL) after 6 weeks of treatment with EZ/Simva 10/20 mg or
Simva 40 mg. p < 0.01
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also significant predictors of goal attainment [24].
Although compliance and therapeutic lifestyle changes
were not assessed in this study, the comparison of the
two treatment regimens did indicate that treatment with
the combination of EZ/Simva 10/20 mg was a significant
positive predictor of achieving LDL-C < 2.6 mmol/L.
Moreover, baseline LDL-C level did not impact this
positive treatment effect, indicating that the odds in
favor of the combination EZ/Simva are maintained for
baseline LDL-C values within the range observed in this
population. These results indicate that EZ/Simva, by tar-
geting both the hepatic synthesis and the intestinal
absorption of cholesterol, may be an effective therapeu-
tic option for patients who have not achieved recom-
mended LDL-C treatment targets with statin
monotherapy.
Several studies or post hoc analyses have assessed
LDL-C lowering and achievement of recommended
treatment targets in patients with T2DM treated with
different doses of EZ/Simva vs statin monotherapy and
showed that the combination provided consistently
greater lipid-lowering and higher goal attainment than
statin monotherapy in patients with and without T2DM
[14,16,26,27]. Most analyses did not include a compari-
son of goal attainment between patient groups, nor an
analysis of factors that predict the odds of achieving
goal. One report, however, showed that more patients in
the diabetes group achieved the recommended LDL-C
goal compared with their non-diabetes counterparts
(83.6% versus 67.2%), although this result was not statis-
tically significant after adjusting for differences in base-
line LDL-C levels [28]. A preliminary report of a post
Figure 3 The odds of achieving LDL-C < 2.6 mmol/L after 6 weeks of treatment with EZ/Simva 10/20 mg or Simva 40 mg by baseline
LDL-C level = 5.0. p < 0.01
Table 2 Summary of tolerability data
EZ/Simva 10/20 mg Simva 40 mg p-value
Safety population n (%) N = 102 N = 111
With adverse events 18 (17.6) 23 (20.7) 0.606
With treatment-related adverse events 10 (9.8) 7 (6.3) 0.500
Discontinued due to treatment-related adverse events 1 (1.0) 2 (1.8) 0.999
Serious adverse events 1 (0.1)* 1 (0.1)† 1.000
ALT/AST ≥ 3 × ULN 0 0 –
CK ≥ 5-10 × ULN 0 0 –
*Bone fracture non-drug related
†Transient ischemic attack, non-drug related
ULN = upper limit of normal
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hoc analysis of patients in the IN-CROSS study demon-
strated a significant interaction for LDL-C lowering,
indicating larger between-group reductions in patients
with T2DM versus those without T2DM [29]. The
results of the logistic regression analysis presented here
indicated nearly three-fold greater odds of achieving the
recommended LDL-C target of < 2.6 mmol/L for
patients included in the LEAD study, which included
only CHD patients with T2DM, vs those included in the
DIALOGUE study, which included only CHD patients
without T2DM. Taken together, these results suggest
that baseline LDL-C may not be the only factor in
achievement of LDL-C < 2.6 mmol/L for patients with
T2DM when compared with patients without T2DM,
since baseline levels were nearly identical in both studies
(~3.3 mmol/L).
Poor response to statin monotherapy and suboptimal
goal achievement in clinical practice may be due to a
number of reasons [30]. Inter-individual variability in
LDL-C lowering has been reported with both high-
potency statins [31] and ezetimibe [32]; and a negative
correlation between the response to statins and the sub-
sequent response to ezetimibe has been shown in
patients with genotype-confirmed heterozygous familial
hypercholesterolemia [32]. The role of cholesterol
homeostasis in response to statins is complex and
unclear, and studies aiming to identify the serum mar-
kers that may be involved in the putative pathway have
not yielded conclusive results, especially in patients with
diabetes [33-38]. From a clinical perspective, however, it
is evident that there is no easily accessible test to deter-
mine if a diabetic patient behaves as a “high absorber”
or as a “high synthesizer” of cholesterol, allowing clini-
cians the ability to target lipid-lowering treatment
accordingly. The response to statin monotherapy with
appropriate potency, dose, and duration is likely the
only way to assess if a patient will attain treatment tar-
gets with statin monotherapy. The results of clinical
trials support a complementary approach that targets
the synthesis and the absorption of cholesterol to
improve the lipid profile of patients who show a poor
response to statin monotherapy [11,12,20].
The tolerability profiles of both treatment regimens
were similar. Although pooling the data from two stu-
dies increased the power of the statistical analysis, the
treatment group sizes were relatively small, and the stu-
dies were not of sufficient duration to detect the pre-
sence of very rare adverse events. Despite these
limitations, the tolerability results are consistent with
expectations for these drugs at the doses given and with
previous trials in high-risk CV patients with and without
T2DM [14-16].
This pooled analysis supports and extends previous
findings that demonstrate the significantly greater
efficacy of the combination EZ/Simva compared with
statin monotherapy in LDL-C reductions and NCEP-
recommended target achievement in high CV risk
patients with and without T2DM. In particular, patients
had significantly higher odds of achieving the NCEP-
recommended LDL-C target when treated with combi-
nation therapy compared with doubling the simvastatin
dose, even at low baseline LDL-C levels. In addition,
EZ/Simva combination therapy was a well-tolerated
treatment. In high CV risk patients with hypercholester-
olemia who have not achieved individual treatment tar-
gets on statin monotherapy, combination therapies such
as EZ/Simva may provide a superior therapeutic option
for improving their lipid profiles. This analysis did not
assess clinical outcomes; however, trials are ongoing to
measure the efficacy of EZ/Simva on clinical outcomes.
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